Qiagen (QGEN) announced that the FDA has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use. This marks the fourth QIAstat-Dx syndromic test to receive U.S. regulatory clearance in 2024.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN: